601.00
+6.50
+(1.09%)
At close: January 10 at 5:29:55 PM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,689,016.00
1,716,850.00
956,340.00
600,570.00
335,997.00
Cost of Revenue
128,755.00
122,348.00
103,265.00
85,352.00
35,284.00
Gross Profit
1,560,261.00
1,594,502.00
853,075.00
515,218.00
300,713.00
Operating Expense
1,278,195.00
1,061,092.00
781,811.00
627,575.00
507,282.00
Operating Income
282,066.00
533,410.00
71,264.00
-112,357.00
-206,569.00
Net Non Operating Interest Income Expense
73,706.00
23,401.00
1,169.00
-1,194.00
-1,347.00
Pretax Income
348,265.00
549,304.00
73,125.00
-111,768.00
-206,579.00
Tax Provision
82,058.00
117,862.00
17,572.00
-21,322.00
-39,314.00
Net Income Common Stockholders
266,207.00
431,442.00
55,553.00
-90,446.00
-167,265.00
Diluted NI Available to Com Stockholders
266,207.00
431,442.00
55,553.00
-90,446.00
-167,265.00
Basic EPS
4.60
7.78
1.01
-1.66
-3.18
Diluted EPS
4.46
7.50
0.97
-1.66
-3.18
Basic Average Shares
57,250.14
55,476.54
55,067.40
54,450.73
52,678.48
Diluted Average Shares
58,946.67
57,497.49
57,170.62
56,227.74
54,615.06
Total Operating Income as Reported
274,559.00
525,903.00
71,956.00
-110,574.00
-205,232.00
Total Expenses
1,406,950.00
1,183,440.00
885,076.00
712,927.00
542,566.00
Net Income from Continuing & Discontinued Operation
266,207.00
431,442.00
55,553.00
-90,446.00
-167,265.00
Normalized Income
266,207.00
431,442.00
50,262.64
-90,446.00
-167,265.00
Interest Income
74,834.00
24,715.00
2,657.00
171.00
194.00
Interest Expense
1,089.00
1,275.00
1,212.00
1,365.00
1,541.00
Net Interest Income
73,706.00
23,401.00
1,169.00
-1,194.00
-1,347.00
EBIT
349,354.00
550,579.00
74,337.00
-110,403.00
-205,038.00
EBITDA
364,368.00
564,566.00
87,273.00
-97,722.00
-193,487.00
Reconciled Cost of Revenue
128,755.00
122,348.00
103,265.00
85,352.00
35,284.00
Reconciled Depreciation
15,014.00
13,987.00
12,936.00
12,681.00
11,551.00
Net Income from Continuing Operation Net Minority Interest
266,207.00
431,442.00
55,553.00
-90,446.00
-167,265.00
Total Unusual Items Excluding Goodwill
--
--
6,961.00
--
--
Total Unusual Items
--
--
6,961.00
--
--
Normalized EBITDA
364,368.00
564,566.00
80,312.00
-97,722.00
-193,487.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
--
--
1,670.64
--
--
12/31/2020 - 12/3/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
SQZB SQZ Biotechnologies Company
0.0300
0.00%
PILA.ST Pila Pharma AB (publ)
4.5700
-2.97%
BIOVIC-B.ST Biovica International AB (publ)
1.9400
+8.87%
ISOFOL.ST Isofol Medical AB (publ)
2.3600
-3.28%
ACE.ST Ascelia Pharma AB (publ)
2.9850
+10.15%
BINV.ST BioInvent International AB (publ)
31.00
-2.67%
5KW.F SkinBioTherapeutics plc
0.1720
+1.18%
7IZ.MU Ziccum AB
0.0298
-29.72%
HQ1.MU Oruka Therapeutics Inc. R
18.60
0.00%
ORN.F Oryzon Genomics S.A.
1.5020
+2.18%